Germ line variants in patients with acute myeloid leukemia without a suspicion of hereditary hematologic malignancy syndrome

Drazer, 2018, Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies, Blood Adv, 2, 146, 10.1182/bloodadvances.2017013037 Furutani, 2017, Germline genetic predisposition to hematologic malignancy, J Clin Oncol, 35, 1018, 10.1200/JCO.2016.70.8644 Carraway, 2020, Myeloid neoplasms with germline predisposition: practical considerations and complications in the search for new susceptibility loci, Best Pract Res Clin Haematol, 33, 101191, 10.1016/j.beha.2020.101191 Tawana, 2018, Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: are we there yet?, Leukemia, 32, 1482, 10.1038/s41375-018-0051-y Godley, 2016, How I diagnose and manage individuals at risk for inherited myeloid malignancies, Blood, 128, 1800, 10.1182/blood-2016-05-670240 Mujahed, 2017, Bone marrow stroma cells derived from mononuclear cells at diagnosis as a source of germline control DNA for determination of somatic mutations in acute myeloid leukemia, Blood Cancer J, 7, e616-12, 10.1038/bcj.2017.93 Kraft, 2020, Identifying potential germline variants from sequencing hematopoietic malignancies, Blood, 2020, 219 Roloff, 2023, Stagnation in quality of next-generation sequencing assays for the diagnosis of hereditary hematopoietic malignancies, J Genet Couns, 32, 744, 10.1002/jgc4.1672 Ley, 2013, Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia, N Engl J Med, 368, 2059, 10.1056/NEJMoa1301689 Papaemmanuil, 2016, Genomic classification and prognosis in acute myeloid leukemia, N Engl J Med, 374, 2209, 10.1056/NEJMoa1516192 Arber, 2022, International Consensus classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data, Blood, 140, 1200, 10.1182/blood.2022015850 Khoury, 2022, The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms, Leukemia, 36, 1703, 10.1038/s41375-022-01613-1 Arber, 2016, The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia, Blood, 127, 2391, 10.1182/blood-2016-03-643544 Yang, 2022, Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML, Blood, 139, 1208, 10.1182/blood.2021011354 Richards, 2015, Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology, Genet Med, 17, 405, 10.1038/gim.2015.30 Li, 2017, Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists, J Mol Diagn, 19, 4, 10.1016/j.jmoldx.2016.10.002 Grimwade, 2010, Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials, Blood, 116, 354, 10.1182/blood-2009-11-254441 Döhner, 2022, Diagnosis and management of AML in adults: 2022 ELN recommendations from an International Expert Panel, Blood, 140, 1345, 10.1182/blood.2022016867 Feliubadaló, 2021, A collaborative effort to define classification criteria for ATM variants in hereditary cancer patients, Clin Chem, 67, 518, 10.1093/clinchem/hvaa250 Tyner, 2018, Functional genomic landscape of acute myeloid leukaemia, Nature, 562, 526, 10.1038/s41586-018-0623-z Welch, 2016, TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes, N Engl J Med, 24, 2023, 10.1056/NEJMoa1605949 Sébert, 2019, Germline DDX41 mutations define a significant entity within adult MDS/AML patients, Blood, 134, 1441, 10.1182/blood.2019000909 Vargas-Parra, 2020, Comprehensive analysis and ACMG - based classification of CHEK2 variants in hereditary cancer patients, Hum Mutat, 41, 2128, 10.1002/humu.24110 Huang, 2018, Pathogenic germline variants in 10,389 adult cancers, Cell, 173, 355, 10.1016/j.cell.2018.03.039 Kim, 2020, Prevalence and clinical implications of germline predisposition gene mutations in patients with acute myeloid leukemia, Sci Rep, 10, 14297, 10.1038/s41598-020-71386-z Feurstein, 2022, Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages, Blood, 140, 2533, 10.1182/blood.2022015790 DeRoin, 2022, Feasibility and limitations of cultured skin fibroblasts for germline genetic testing in hematologic disorders, Hum Mutat, 43, 950, 10.1002/humu.24374 Wong, 2016, Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML, Blood, 127, 893, 10.1182/blood-2015-10-677021 Hasserjian, 2020, Clonal hematopoiesis and measurable residual disease assessment in acute myeloid leukemia, Blood, 135, 1729, 10.1182/blood.2019004770 Tanaka, 2021, Clonal dynamics and clinical implications of postremission clonal hematopoiesis in acute myeloid leukemia, Blood, 138, 1733, 10.1182/blood.2020010483 Suarez, 2015, Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the french national registry of primary immune deficiencies, J Clin Oncol, 33, 202, 10.1200/JCO.2014.56.5101 Viniou, 2001, Acute myeloid leukemia in a patient with ataxia-telangiectasia: a case report and review of the literature, Leukemia, 15, 1668, 10.1038/sj.leu.2402210 Lin, 2010, Child with ataxia telangiectasia developing acute myeloid leukemia, J Clin Oncol, 28, 213, 10.1200/JCO.2009.25.5067 Brioli, 2011, Patient with ataxia telangiectasia who developed acute myeloid leukemia, Leuk Lymphoma, 52, 1818, 10.3109/10428194.2011.577256 Onoda, 2013, Successful treatment of acute myeloid leukaemia in a patient with ataxia telangiectasia, Eur J Haematol, 91, 557, 10.1111/ejh.12186 Goldgraben, 2020, Genomic profiling of acute myeloid leukaemia associated with ataxia telangiectasia identifies a complex karyotype with wild-type TP53 and mutant KRAS, G3BP1 and IL7R, Pediatr Blood Cancer, 67, e28354, 10.1002/pbc.28354 Renwick, 2006, ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles, Nat Genet, 38, 873, 10.1038/ng1837 Roberts, 2012, ATM mutations in patients with hereditary pancreatic cancer, Cancer Discov, 2, 41, 10.1158/2159-8290.CD-11-0194 Pritchard, 2016, Inherited DNA-repair gene mutations in men with metastatic prostate cancer, N Engl J Med, 375, 443, 10.1056/NEJMoa1603144 Dalmasso, 2021, Germline ATM variants predispose to melanoma: a joint analysis across the GenoMEL and MelaNostrum Consortia, Genet Med, 23, 2087, 10.1038/s41436-021-01240-8 Roloff, 2021, Assessment of technical heterogeneity among diagnostic tests to detect germline risk variants for hematopoietic malignancies, Genet Med, 23, 211, 10.1038/s41436-020-0934-y Aguilera-Diaz, 2020, Assessment of the clinical utility of four NGS panels in myeloid malignancies. Suggestions for NGS panel choice or design, PLoS One, 15, e0227986, 10.1371/journal.pone.0227986 Choi, 2016, ATM mutations in cancer: therapeutic implications, Mol Cancer Ther, 15, 1781, 10.1158/1535-7163.MCT-15-0945 Li, 2022, AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome, Leukemia, 36, 664, 10.1038/s41375-021-01404-0 Bick, 2020, Inherited causes of clonal haematopoiesis in 97,691 whole genomes, Nature, 586, 763, 10.1038/s41586-020-2819-2 Stubbins, 2022, Germline CHEK2 and ATM variants in myeloid and other hematopoietic malignancies, Curr Hematol Malig Rep, 17, 94, 10.1007/s11899-022-00663-7 Janiszewska, 2018, Constitutional mutations of the CHEK2 gene are a risk factor for MDS, but not for de novo AML, Leuk Res, 70, 74, 10.1016/j.leukres.2018.05.013 Lindsley, 2015, Acute myeloid leukemia ontogeny is defined by distinct somatic mutations, Blood, 125, 1367, 10.1182/blood-2014-11-610543 Klco, 2021, Advances in germline predisposition to acute leukaemias and myeloid neoplasms, Nat Rev Cancer, 21, 122, 10.1038/s41568-020-00315-z del Valle, 2020, Exploring the role of mutations in Fanconi anemia genes in hereditary cancer patients, Cancers, 12, 829-10, 10.3390/cancers12040829 Aalbers, 2013, Absence of SBDS mutations in sporadic paediatric acute myeloid leukaemia, Br J Haematol, 160, 559, 10.1111/bjh.12134 Peterlongo, 2015, FANCM c. 5791C>T nonsense mutation (rs144567652) induces exon skipping , affects DNA repair activity and is a familial breast cancer risk factor, Hum Mol Genet, 24, 5345, 10.1093/hmg/ddv251 Ward, 1999, Novel point mutation in the extracellular domain of the granulocyte colony-stimulating factor (G-CSF) receptor in a case of severe congenital neutropenia hyporesponsive to G-CSF treatment, J Exp Med, 190, 497, 10.1084/jem.190.4.497 Triot, 2014, Inherited biallelic CSF3R mutations in severe congenital neutropenia, Blood, 123, 3811, 10.1182/blood-2013-11-535419 Klimiankou, 2015, GM-CSF stimulates granulopoiesis in a congenital neutropenia patient with loss-of-function biallelic heterozygous CSF3R mutations, Blood, 126, 1865, 10.1182/blood-2015-07-661264 Skokowa, 2017, Severe congenital neutropenias, Nat Rev Dis Primers, 3, 1, 10.1038/nrdp.2017.32 Lavallée, 2016, Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors, Blood, 127, 3054, 10.1182/blood-2016-03-705053 Zhang, 2018, CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia, Cancer, 124, 3329, 10.1002/cncr.31586 Wang, 2022, Differential implications of CSF3R mutations in t(8;21) and CEBPA double mutated acute myeloid leukemia, Clin Lymphoma Myeloma Leuk, 22, 393, 10.1016/j.clml.2021.11.013 Trottier, 2020, Heterozygous germ line CSF3R variants as risk alleles for development of hematologic malignancies, Blood Adv, 4, 5269, 10.1182/bloodadvances.2020002013 Senol-cosar, 2019, Considerations for clinical curation, classification, and reporting of low-penetrance and low effect size variants associated with disease risk, Genet Med, 21, 2765, 10.1038/s41436-019-0560-8 Feurstein, 2022, A practical guide to interpreting germline variants that drive hematopoietic malignancies, bone marrow failure, and chronic cytopenias, Genet Med, 24, 931, 10.1016/j.gim.2021.12.008